Acelity acquires Crawford Healthcare

Transaction adds complementary key product platforms, significant commercial scale and R&D expertise to Acelity

Mel J. Yeates
Register for free to listen to this article
Listen with Speechify
San Antonio, Tx. and Cheshire, U.K.—Today Acelity L.P. Inc., the world’s largest wound care company, and Crawford Healthcare, a rapidly growing UK-based advanced wound care and dermatology company, announced an agreement for Acelity to acquire Crawford and all of its assets. The terms of the agreement have not been disclosed.
With the acquisition of Crawford, Acelity expands its portfolio of advanced wound dressings (AWD), further strengthening its position as a global leader in advanced wound healing. Crawford Healthcare is a recognized leader in developing and commercializing innovative treatments for the care and repair of skin. Crawford’s wound dressing portfolio includes the market-leading super-absorbent KerraMax Care range and the absorbent KerraFoam and KerraCel in the foam and antimicrobial gelling fiber AWD categories, respectively.
Crawford Healthcare also brings to the table the KerraContact Ag silver wound dressing, the hydrogel KerraLite Cool range and the KerraPro pressure ulcer-reducing range, as well as other preventative technologies. This expanded line of advanced wound dressings, combined with Acelity’s industry-leading negative pressure wound therapy platforms, reportedly forms the world’s most expansive wound care portfolio. In addition to its commercial products, Acelity will acquire Crawford’s innovative R&D capabilities and manufacturing operations based in Cheshire.
“Crawford’s talented team, highly complementary line of advanced wound dressings, and track record of patient-focused innovation make them a terrific partner to accelerate our global growth,” said R. Andrew Eckert, President and CEO of Acelity. “This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments; expand and strengthen our customer relationships; and enhance our innovation expertise for the benefit of clinicians and patients around the world.”
Crawford’s advanced wound dressing lines complement Acelity’s existing AWD portfolio, which includes the market-leading collagen dressing PROMOGRAN PRISMA Matrix, as well as the TIELLE dressing family and ADAPTIC dressings. According to their website, Acelity has a comprehensive range of wound care products and therapies for a variety of applications ranging from acute and traumatic wounds, diabetic foot ulcers, enteric fistulas and infected wounds to pressure ulcers and venous leg ulcers. Acelity also has products for open abdomen management, as well as products for incision management, epidermal harvesting and animal health products for use in veterinary medicine.
Richard Anderson, chief executive of Crawford Healthcare noted, “The rapid growth of the business has been possible due to our focused investment in innovative products which are clinically proven to improve patient outcomes. Becoming part of the world’s largest wound care company will provide us with the scale to optimize our potential within the US, the largest global market and the ability to further access and grow in other international markets with our best-in-class advanced wound care products.”
Anderson will continue to lead Crawford Healthcare at present, and its products will remain fully available to clinicians and customers as the two companies work together to form integration plans for the remainder of the year.

Mel J. Yeates

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue